Mesothelioma Community Will Convene to Focus on Cure

SANTA BARBARA, Calif., Sept. 22 /PRNewswire/ -- The urgent mission to improve treatments for a deadly, asbestos-related cancer will make another step forward, the Mesothelioma Applied Research Foundation (MARF) announced today, with the Second International Symposium on Malignant Mesothelioma.

Meso is a malignant tumor that aggressively invades the linings of the lungs, abdomen, heart or testicles. The need for research to develop effective treatments was neglected for decades. But in the past few years, exciting progress has begun. MARF, the national nonprofit whose mission is to eradicate meso as a life-ending disease, has organized the Symposium to review this progress, elucidate the latest advances, and strengthen and encourage the entire meso community.

The Symposium will be held in Las Vegas at the Caesars Palace convention center, October 6 through 8. Following the highly successful 2004 format, the program combines highly relevant material for the patient/family and advocacy communities with scientific presentations by leading experts on the latest in meso science and treatment.

The Symposium will open powerfully with presentations on the scope of the mesothelioma tragedy and the continuing threat, by Dr. Stephen Levin from the renowned Mount Sinai Irving Selikoff Center for Occupational and Environmental Medicine, author and Pulitzer Prize winning journalist Andrew Schneider, and international experts Michael Harbut and Michele Carbone.

Sessions focused specifically for patients and caregivers will cover the clinical aspects of the disease and its treatment, including surgery, chemotherapy, experimental treatments, and pain management. Extended break-out sessions are planned for patients, caregivers and the bereaved, to offer holistic strategies for the emotional, physical and psychological aspects of the disease.

Major scientific topics will include evolving diagnostic, prognostic and staging technologies, including the latest in early detection. Multi-modal management -- surgery, radio and chemotherapy -- will be covered in detail for both pleural and peritoneal meso. Systemic chemotherapy protocols will be reviewed, including an assessment of the Alimta/Cisplatin regimen. Second line and novel treatment approaches will be discussed, along with a thorough overview of meso research projects currently underway. Participating physicians will receive CME credits for these sessions. Patients, family members and other non-medical professionals are also welcome to attend.

News Source: PR Newswire  |  Published: October 3, 2005  |  Read Full Story

 

Contact an Asbestos and Mesothelioma Attorney, Lawyer, Law Firm

Please fill out the form below to contact an attorney. Provide as much information as possible to speed the processing of your inquiry (Only United States residents are eligible).

Contact Information
  *Are required items.
*First Name:
*Last Name:
Email Address:
*Daytime Phone:
Evening Phone:
*Zip Code:
Case Information
Have you, or the person you are contacting us on behalf of, been diagnosed with mesothelioma:
Yes:   No:
Date of diagnosis:

*Comments: (Please describe your legal issues and needs.)

Terms
I understand submission of information submission of information for review does not create, is not intended to create, and must not be relied upon as creating, an attorney-client relationship. I understand such a relationship can only be created by the agreement of both the client and the attorney, evidenced by a written retainer agreement that has been signed by client and counter-signed by the attorney.

By submitting your expression of interest you are consenting to receive telephone calls from participating law firms even if you are currently on the do-not-call list.

*I Agree to these terms: